Argenica Therapeutics (AGN) H2 2025 earnings summary

Executive summary

• Completed dosing of final patient in Phase 2 clinical trial for ARG-007 in acute ischaemic stroke; topline data expected early September 2025.

• Robust preclinical data for ARG-007 in moderate traumatic brain injury; established a Clinical Advisory Committee for TBI development.

• Received over $4 million in non-dilutive grants and philanthropic funding to support ongoing studies.

Financial highlights

• Revenue for FY2025 was $3,726,499, up from $2,790,022 in FY2024, mainly from R&D tax incentives, grants, and interest income.

• Net loss after tax increased to $7,170,347 (FY2024: $5,479,488), driven by higher R&D expenses.

• R&D costs rose to $8,132,295 (FY2024: $6,016,753), reflecting expanded clinical and preclinical activities.

• Cash and cash equivalents at year-end were $10,555,160 (FY2024: $15,912,660).

• Net assets at 30 June 2025 were $7,237,271 (FY2024: $13,950,835).

Outlook and guidance

• Topline results from the Phase 2 ARG-007 trial expected in early September 2025.

• Additional non-dilutive funding of up to $1.5 million awarded under the MRFF program, with $1 million secured post-year-end.

• Ongoing engagement with the FDA to lift the clinical hold on the IND for ARG-007 in the US.